Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Varsha Gandhi, PhD, on Ibrutinib

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Oct
01
Today In Oncology
Depression Increases Cancer-Specific Mortality Risks in Common Cancers
Real-World Data Indicate Lower Adherence Rates for Breast Cancer Endocrine Therapy When Radiation Therapy Is Omitted
SYMPRO-Lung: Could Weekly PRO Symptom Monitoring Improve Survival Outcomes in Any-Stage Lung Cancer?
Mindfulness and Tai Chi May Improve Symptoms After Cancer Treatment
Cleveland Clinic to Host Second Annual AI Summit for Health-Care Professionals
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo